HANSOH PHARMA (03692): Injection of Reconnective Votutamab (HS-20093) for the treatment of osteosarcoma included in the priority review and approval process of the National Medical Products Administration
HANSOH PHARMA (03692) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (reconnective votutamab for injection) (the Product), the indication of the Product for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy has been included in the priority review and approval process of China's National Medical Products Administration (NMPA).
HANSOH PHARMA (03692) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (reconnective votutamab for injection) (the product), the indication of the product for the treatment of osteosarcoma patients aged 12 years who have failed at least two prior lines of therapy has been included in the priority review and approval process of China's National Medical Products Administration (NMPA).
Related Articles
Farewell to the real estate label, Dexiang (00199) adopts the new abbreviation "Dexiang New Cloud Computing"
BQD (03866) has completed the issuance of RMB 500 million in financial bonds.
Ningxia Younglight Chemicals (000635.SZ): Partial facilities temporarily shut down
Farewell to the real estate label, Dexiang (00199) adopts the new abbreviation "Dexiang New Cloud Computing"
BQD (03866) has completed the issuance of RMB 500 million in financial bonds.
Ningxia Younglight Chemicals (000635.SZ): Partial facilities temporarily shut down
